|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT02941874 |
|
Date of registration:
|
17/10/2016 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Marker of the Cellular Captation of Glucose: the IRAP Protein
IRAP |
|
Scientific title:
|
Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Specific Marker of the Cellular Captation of Glucose: the IRAP Protein (Insulin Regulated AminoPeptidase) |
|
Date of first enrolment:
|
April 7, 2017 |
|
Target sample size:
|
96 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02941874 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Body mass index between 19 and 25 Kg/m²
- No intercurrent disease during the last week
- No chronic infectious disease
- No smoker, no alcoholic
Exclusion Criteria:
- history of : thyroid disease, liver or renal disease, endocrine and metabolic disease,
cardiovascular disease, lung disease, gastroenterological disorders, psychiatric
disease, Epilepsy
- Consumption of narcotic drug
- Blood donation dating less than 2 months
- Pregnancy or breast-feeding, or intent to become pregnant during the study period
- legal exclusion criteria
Age minimum:
40 Years
Age maximum:
70 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Insulin Resistance
|
|
Intervention(s)
|
|
Other: Blood sample collection during an OGTT to assess IRAP blood concentration
|
|
Primary Outcome(s)
|
|
Normal values of IRAP concentration will be calculated by making the average of the three dosages of IRAP measured at base line.
[Time Frame: At the beginning of the second visit of the study, before the glucose intake]
|
|
Secondary Outcome(s)
|
|
Repeatability of the IRAP measurement
[Time Frame: At the beginning of the second visit of the study, before the glucose intake]
|
|
Temporal reproducibility of the concentration of IRAP
[Time Frame: At the beginning of the second visit of the study, before the glucose intake]
|
|
Secondary ID(s)
|
|
38RC16.131
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|